Effects of picotamide on release of endothelin-1, thromboxane, and prostacycline after treadmill stress in patients with peripheral artery disease

Angiology

Volumn 49, Issue 11, 1998, Pages 879-884

  Saitta, Antonino ^a,b   Sardo, Adriana ^a   Bonaiuto, Michele ^a   Giordano, Giuseppe ^a   Imbalzano, Egidio ^a   Castaldo, Maria ^a   Cinquegrani, Maurizio ^a   D'Arrigo, Daniele ^a   Campo, Giuseppe M ^a   Squadrito, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Department of Internal Medicine ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; PICOTAMIDE; PLACEBO; PROSTACYCLIN; THROMBOXANE; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; EXERCISE TEST; FEMALE; HUMAN; ISCHEMIA; MALE; ORAL DRUG ADMINISTRATION; TREADMILL EXERCISE;

EID: 15644371881     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979804901102     Document Type: Article

References (14)

1. Antiplatelet Trialist Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296:320-321, 1988.
2. Moncada S, Vane JR: Arachidonic acid and the interaction between platelets and blood vessel walls. N Engl J Med 300:1142-1147, 1979.
3. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231:232-235, 1971.
4. 2 receptor antagonist in human platelets. Thromb Haemost 61:479-484, 1989.
5. 2 inhibitor: Importance of activated monocytes. Coron Artery Dis 5:137-145, 1994.
6. Neirotti M, Molaschi M, Ponzetto M, et al: Hemodynamic, hemorrheologic, and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs. Angiology 45:137-141, 1994.
7. Balsano F, Violi F, and the ADEP Group: Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. Circulation 87:1563-1569, 1997.
8. Yanagisa MA, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 322:411-415, 1988.
9. Lerman A, Edwars BS, Hallet JW, et al: Circulation and tissue endothelin immunoreactivity in advance atherosclerosis. N Engl J Med 325:997-1003, 1991.
10. DeNucci A, Thomas R, D'Orleans-Juste P, et al: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85:9797-9800, 1988.
11. Hirata Y, Takagi Y, Fucuda Y, et al: Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78:225-228, 1989.
12. Wright CD, Cody W, Dunbar JB, et al: Characterization of the chemotactic activity of endothelins and peptide fragments for human neutrophils. FASEB J 5:A637, 1991.
13. 2+ channel in vascular smooth muscle. Proc Natl Acad Sci USA 86:3915-3918, 1989.
14. Hieda HS, Gomez Sanches CE: Hypoxia increases endothelin release in bovine endothelial cells in culture but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not. Life Sci 47: 247-251, 1990.